Merck Announces Phase 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of Overall Survival (OS) as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

These OS results build on positive data previously reported from KEYNOTE-811 that supported its FDA-approved indication

...

Related Keywords

Canada ,United States , ,Merck Research Laboratories ,Youtube ,Instagram ,Twitter ,Facebook ,Drug Administration ,Merck Co Inc ,Linkedin ,European Society For Medical Oncology ,Statement Of Merck Co Inc ,Exchange Commission ,Marjorie Green ,Merck Research ,European Society ,Medical Oncology ,Important Safety Information ,Selected Important Safety ,Fatal Immune Mediated Adverse ,Single Agent ,Thyroid Disorders ,Which Can Present With Diabetic Ketoacidosis ,Nervous System ,Connective Tissue ,Patients With Multiple Myeloma ,Neck Squamous Cell Cancer ,Bacillus Calmette Guerin ,Mismatch Repair Deficient Cancer ,Mismatch Repair Deficient Colorectal Cancer ,Looking Statement ,Securities Litigation Reform Act ,Annual Report ,Markets ,